CSPG4 and melanoma: Ulmer et al. [58] and then Suesskind et al. [59] used the anti-melanoma-associated chondroitin sulphate proteoglycan (MCSP) antibody conjugated with microbeads and identified CTCs in 19% and 14% of UM patients, respectively.